Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908996 | 0.85 | THRB (0.35) | RORCTHRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL4537452 | 0.83 | THRB (0.35) | RORCTHRBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1038940 | 0.82 | RORC (0.32) | RORCTHRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL1038944 | 0.81 | TDP1 (0.33) | RORCTHRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL1040374 | 0.81 | MMP9 (0.36) | THRBMAPTALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3906126 | 0.80 | RORC (0.34) | RORCCYP2C9KMT2AREN | |
| SCHEMBL3915719 | 0.80 | PKM (0.39) | MAPTALDH1A1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL3907440 | 0.79 | PKM (0.38) | ALDH1A1CYP2C9KMT2ALMNATP53 | |
| SCHEMBL2915001 | 0.79 | FKBP1A (0.38) | RORCMAPTALDH1A1CYP2C9KMT2A | |
| SCHEMBL2922725 | 0.78 | KMT2A (0.36) | RORCMAPTALDH1A1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | RORC 4614/4885THRB 2871/4885MAPT 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.